RU2004123099A - Полифенольное ингибирование активности нуклеозиддифосфаткиназы в и метастазирование рака - Google Patents

Полифенольное ингибирование активности нуклеозиддифосфаткиназы в и метастазирование рака Download PDF

Info

Publication number
RU2004123099A
RU2004123099A RU2004123099/15A RU2004123099A RU2004123099A RU 2004123099 A RU2004123099 A RU 2004123099A RU 2004123099/15 A RU2004123099/15 A RU 2004123099/15A RU 2004123099 A RU2004123099 A RU 2004123099A RU 2004123099 A RU2004123099 A RU 2004123099A
Authority
RU
Russia
Prior art keywords
activity
nucleoside
nucleoside diphosphate
diphosphate kinase
diphosphatkinase
Prior art date
Application number
RU2004123099/15A
Other languages
English (en)
Inventor
Ян БАКСТОН (US)
Ян БАКСТОН
Original Assignee
Рисерч Дивелопмент Фаундейшн (US)
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн (US), Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн (US)
Publication of RU2004123099A publication Critical patent/RU2004123099A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91235—Phosphotransferases in general with a phosphate group as acceptor (2.7.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (4)

1. Способ скрининга на предмет отбора соединения, которое ингибирует ангиогенез опухолевых клеток, включающий в себя стадии определения активности нуклеозиддифосфаткиназы В в присутствии или отсутствии указанного соединения, где снижение активности нуклеозиддифосфаткиназы В в присутствии указанного соединения свидетельствует о том, что указанное соединение ингибирует ангиогенез опухолевой клетки.
2. Способ ингибирования ангиогенеза опухолевой клетки, включающий в себя стадию контактирования указанной клетки с ингибитором активности нуклеозиддифосфаткиназы В.
3. Способ по п.2, где указанный ингибитор нуклеозиддифосфаткиназы В выбран из группы, состоящей из эллагиковой кислоты, галлата эпигаллокатехина и галлата эпикатехина.
4. Способ ингибирования активности нуклеозиддифосфаткиназы В в опухолевой клетке, включающий в себя стадию контактирования указанной клетки с эллагиковой кислотой или структурно подобным аналогом, галлатом эпигаллокатехина или структурно подобным аналогом или галлатом эпикатехина или структурно подобным аналогом.
RU2004123099/15A 2001-12-28 2002-12-30 Полифенольное ингибирование активности нуклеозиддифосфаткиназы в и метастазирование рака RU2004123099A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34432101P 2001-12-28 2001-12-28
US60/344,321 2001-12-28

Publications (1)

Publication Number Publication Date
RU2004123099A true RU2004123099A (ru) 2005-04-20

Family

ID=32823676

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004123099/15A RU2004123099A (ru) 2001-12-28 2002-12-30 Полифенольное ингибирование активности нуклеозиддифосфаткиназы в и метастазирование рака

Country Status (7)

Country Link
US (1) US7678549B2 (ru)
EP (1) EP1458404A4 (ru)
AU (1) AU2002357399A1 (ru)
CA (1) CA2471750A1 (ru)
IL (1) IL162760A0 (ru)
RU (1) RU2004123099A (ru)
WO (1) WO2003057239A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068864B1 (en) 2006-04-26 2017-08-23 The Regents of the University of California Therapeutic uses of urolithins
KR20080108797A (ko) * 2007-06-11 2008-12-16 국립암센터 Ｅｇｃｇ를 포함하는 트란스글루타미나제 억제제 및 그의제조방법
AU2013350721A1 (en) * 2012-11-29 2015-01-29 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
CN108330160A (zh) * 2018-04-18 2018-07-27 易尚明天科技有限公司 核苷二磷酸激酶ndpk活性的检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900473D0 (sv) * 1999-02-12 1999-02-12 Karolinska Innovations Ab Inhibitor of endothelial cell proliferation
JP2002537793A (ja) 1999-03-02 2002-11-12 ザ ユニヴァーシティー オブ ダンディー 変更したＮＤＰＫ機能を決定する方法及び嚢胞性線維症の診断法（ｄｉａｇｎｏｓｉｓ）
WO2000057875A1 (en) * 1999-03-30 2000-10-05 Purdue Research Foundation Compositions containing tea catechins as cancer specific proliferation inhibitors
US6248341B1 (en) * 2000-01-14 2001-06-19 Color Access, Inc. Method of treating topical angiogenesis-related disorders

Also Published As

Publication number Publication date
EP1458404A1 (en) 2004-09-22
EP1458404A4 (en) 2006-04-26
US20030175834A1 (en) 2003-09-18
WO2003057239A1 (en) 2003-07-17
IL162760A0 (en) 2005-11-20
CA2471750A1 (en) 2003-07-17
US7678549B2 (en) 2010-03-16
AU2002357399A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
DZ3004A1 (fr) Omega-carboxyaryl diphényl urées substitués comme inhibiteurs de raf kinase.
CA2400447A1 (en) Kinase inhibitors
CY2014034I2 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
ATE399007T1 (de) Raf kinase hemmer
EP1205478A4 (en) P38MAP KINASE INHIBITORS
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
ATE381557T1 (de) Rho-kinase inhibitoren
WO2006050012A3 (en) Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
NO971684L (no) Nye benzoxazoler
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
DE60135243D1 (de) Beschichtung zur verhinderung von erosion an bohrlochbauteilen
PT1171440E (pt) 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
RU2004123099A (ru) Полифенольное ингибирование активности нуклеозиддифосфаткиназы в и метастазирование рака
JO2317B1 (en) Inhibitors of the 8-aryl quinoline phosphodiesterase substituted enzyme
WO2002036578A3 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
NO20024879D0 (no) Fremgangsmåte ved påvisning av celler
MXPA03001484A (es) Quinazolinas, medicamentos que contienen estos compuestos, y son efectivos como inhbidores de tirosina quinasa, su utilizacion y metodos para su produccion.
EP1291439A3 (en) Method for identifying metalloenzyme inhibitors
WO2003066885A3 (en) Method for screening for compounds having hdac inhibitory activity
DE1206274T1 (de) Verwendung von interleukin-18-inhibitoren zur hemmung von tumormetastasierung
ITBO990293A0 (it) Metodo di controllo di banconote .
WO2002039990A3 (en) Method for screening anti-proliferative compounds and inhibiting tumor growth
DE69941292D1 (de) Schlange, pseudonaja textilis textilis
WO2001007659A3 (en) Methods for identifying inhibitors of signaling molecules

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070412